ETS 005
Alternative Names: ETS-005Latest Information Update: 28 Jun 2024
At a glance
- Originator ETERN Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Cancer in China (unspecified route) before April 2024
- 05 Apr 2024 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical study in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 ETERN Therapeutics plans a phase I trial for Cancer in 2024